ACTRN12619000372189招募中1 期
A Multicenter, Patient and Investigator-Blinded, Placebo-Controlled Proof-Of-ConceptStudy to Determine the Safety, Tolerability and Central Nervous System (CNS) Exposureof Oral RTB101 and Sirolimus Alone or in Combination in Patients with Mild-ModerateParkinson’s Disease (PD).
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Patient must be able to communicate well with the Investigator, and to
- •understand and comply with the requirements of the study.
- •- Signed informed consent must be obtained before any study assessment is
- •- Male and female adults 18 years of age and older at the time of informed
- •consent signing
- •- Patients must weigh greater than or equal to 40 kg and less than or equal to 150 kg at Baseline Visit.
- •- Diagnosis of PD with a mH&Y stage of less than or equal to 2 at screening
- •- Stable medication regimen of PD drugs for at least 30 days (at least 60
- •days for rasagiline) prior to first dose (Day 0, Visit 3).
- •- At screening and baseline, vital signs (systolic and diastolic blood
- •pressure (BP), pulse rate and body temperature) will be assessed in a sitting
- •position after the patient has rested for at least three minutes. Sitting vital
- •signs must be within the following ranges:
- •Oral or tympanic body temperature between 35.0-37.5°C
- •Systolic BP, 90-160 mm Hg
- •Diastolic BP, 50-95 mm Hg
- •Heart rate, 40-95 bpm
排除标准
- •-Parkinsonism due to drug(s) or toxin(s) or with history of a prior brain
- •magnetic resonance imaging (MRI) without contrast, showing a structural
- •abnormality that is a possible cause of their PD signs or symptoms
- •-Patients with prior surgical history of deep brain stimulation (DBS).
- •-If female, pregnancy (defined as positive beta-human chorionic
- •gonadotrophin [b-hCG] blood test), lactating or breast-feeding.
- •-Women of childbearing potential (any woman physiologically capable of
- •becoming pregnant) unless they remain on highly effective methods of
- •contraception (see below) throughout the study and for 12 weeks
- •following discontinuation of the study drug.
- •-Sexually active male patients with a partner of childbearing
- •potential must be willing to wear a condom while on study drug
- •and for 12 weeks after stopping study drug and should not father a child
- •in this period. A condom is required to be used also by vasectomized men
- •with a partner of child-bearing potential in order to prevent delivery of
- •the drug via seminal fluid.
- •-Use of other investigational drugs within 5 half-lives of randomization, or
- •within 30 days, whichever is longer; or longer if required by local
- •regulations.
- •-History of hypersensitivity or allergy to sirolimus, RTB101 or their
- •excipients or to other mTOR inhibitor drugs.
- •-Concomitant use of any of the drugs (including strong CYP3A4 inhibitors or inducers, angiotensin-converting-enzyme (ACE) inhibitors, anti-coagulants) or other treatments (including live vaccines)
- •-Any one of the following hematologic or coagulation abnormalities at
- •Haemoglobin <10.0 g/dL for males and <9.0 g/dL for females
- •White blood cell count (WBC) <3,500/mm3
- •Neutrophil count <2,000/mm3
- •Platelet count <125,000/mm3
- •International normalized ratio (INR) >1.2
- •Partial prothromboplastin time (PTT) >35 seconds.
- •-Patients receiving immunosuppressive therapy including chronic use of
- •prednisone >10 mg daily.
- •- Patients with active or chronic infection other than fungal skin or nail infection or local herpes simplex infection.
- •-Immunodeficiency diseases, including a positive human immunodeficiency virus (HIV) test result; or chronic infection with Hepatitis B virus (HBV) or Hepatitis C virus (HCV).
- •-Recent surgery (involving entry into a body cavity or requiring sutures) within 2 months of the Screening Visit or any evidence of unhealed surgical wound or lack of significant recovery from the surgery (minor skin surgery is allowed within 2 months of Screening provided the surgical wound has healed).
- •-Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of drugs, or which may jeopardize the patient in case of participation in the study.
- •-Patients with insulin-dependent diabetes mellitus (Type 1 or 2)
- •-Patients with significant uncontrolled hypercholesterolemia
- •-History of malignancy in any organ system, treated or untreated, within the past 3 years, regardless if there is evidence of local recurrence or metastases, except for localized basal cell or squamous cell carcinoma of the skin. History of malignancy in any organ system, treated or untreated, within the past 3 years, regardless if there is evidence of local recurrence or metastases, except for:
- •Treated localized basal cell carcinoma of the skin.
- •Prostate cancer confined to the gland (AJCC stage T2N0M0 or better).
- •Treated cervical carcinoma in situ.
研究者
相似试验
进行中（未招募）
1 期
A multicenter study to evaluate pharmacokinetics, safety and tolerability of TIN816 in patients with sepsis-associated acute kidney injuryEUCTR2022-000887-23-DEovartis Pharma AG20
招募中
1 期
A multicenter study to evaluate pharmacokinetics, safety and tolerability of TIN816 in patients with sepsis-associated acute kidney injuryEUCTR2022-000887-23-ESovartis Farmacéutica, S.A.20
进行中（未招募）
1 期
A multicenter study to evaluate pharmacokinetics, safety and tolerability of TIN816 in patients with sepsis-associated acute kidney injuryEUCTR2022-000887-23-HUovartis Pharma AG20
进行中（未招募）
1 期
Evaluation of the efficacy and safety of a new formulation (Cream) for the treatment of psoriasis vulgaris in adults as compared to a product already availible on the market and placebo.EUCTR2018-001970-66-CZMC2 Therapeutics Ltd.490
进行中（未招募）
1 期
Evaluation of the efficacy and safety of a new formulation (Cream) for the treatment of psoriasis vulgaris in adults as compared to a product already availible on the market and placebo.EUCTR2018-001970-66-DEDrug Delivery SolutionsLtd (Part of MC2 Therapeutics)490